Skip to main content
Matthew McKinney, MD, Oncology, Durham, NC

MatthewStuartMcKinneyMD

Oncology Durham, NC

Cancer Genetics/Cancer Risk Assessment, Cutaneous Lymphoma, HIV/AIDS Related, Hematologic Oncology

Assistant Professor of Medicine at Duke University Medical Center, Department of Medicine, Division of Hematologic Malignancies

Dr. McKinney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. McKinney's full profile

Already have an account?

  • Office

    20 Duke Medicine Circle
    Durham, NC 27710
    Phone+1 919-684-8964
    Fax+1 919-684-5325

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2006 - 2009
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2006

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2006 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
    Matthew S. McKinney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma
    Matthew S. McKinney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
    Hepatosplenic T-cell Lymphoma: Recent Progress and Future ConsiderationsSeptember 16th, 2020